Our Roadmap
Q2 2019
Founding of Visotec GmbH
Visotec GmbH is founded by Helge Sudkamp, Peter Koch, Moritz Moltmann, and Michael Münst.
Q1 2020
Malte joins Visotec as a data scientist
Visotec is growing! Malte joins the team as a data scientist. His tasks include the development of evaluation algorithms for clinical data, image processing, and IT-Infrastructure.
Q2 2020
Visotec now owns the entire IP to protect its technology
We possess all six patent families protecting the technology.
Visotec successfully finishes first clinical trial
We successfully finish the first clinical trial. We reach a sensitivity and specificity of 0.94 and 0.95 in comparison to the gold standard regarding the decision of whether or not Anti-VEGF treatment is necessary. Please check our white paper for a full summary of the study results.
July 2020.
Visotec moves out of University

Q4 2020
Current engineering unit, V6
Our newest engineering unit contains our latest state-of-the-art technology and demonstrates its operation principle.
We are here.
Q1 2022
Development of CE-marked, handheld OCT device
We develop a CE-marked pilot product for the next generation of clinical studies. This primarily includes the home care study, but also the development of treatment schemes with collaborating physicians.
Study: Acquisition of follow-up clinical data to reveal the full potential of a home care OCT system
This study includes patients performing OCT scans on a daily basis for the first time. The close monitoring enables us to visualize the progression of the disease on a new level.
As AI algorithms require a wide ground truth we are also able to use the acquired data to sharpen the precision of our AI algorithms. This helps to detect biomarkers of age-related macular degeneration in an early stage to provide carefree treatment.
Q1 2023
Study: OCT@Home demonstrating independent operation by the patient and improved subsequent treatment
Based on the CE-marked handheld device, this study involves patients using the device at home. The study shows that patients can use the device reliably and regularly in their own homes. We are able to determine the clinical value from daily follow-up OCT measurements compared to standard (monthly) diagnostics.
Q2 2023
Development of scalable consumer product
This step streamlines the CE-marked device for efficient and scalable production.
Q4 2023
Study: Validating home-based OCT treatment schemes
This study validates home-based OCT treatment schemes.
Visotec is looking for investors.
If you are interested, we would be happy to hear from you.